Michael Gelband’s Praxis Precision Medicines PRAX Stock Holding History

Michael Gelband’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,742	Closed	-$4.75M	–	1956
2026 Q1	$4.75M	Buy	+14,742	New	+$4.56M	0.04%	453
2025 Q2	–	Sell	-39,975	Closed	-$1.51M	–	1878
2025 Q1	$1.51M	Buy	+39,975	New	+$2.5M	0.02%	803
2023 Q1	–	Sell	-2,824	Closed	-$101K	–	2051
2022 Q4	$101K	Sell	2,824 -1,457	-34%	-$45.4K	﹤0.01%	1517
2022 Q3	$146K	Sell	4,281 -2,640	-38%	-$132K	﹤0.01%	1696
2022 Q2	$254K	Buy	+6,921	New	+$739K	﹤0.01%	1590

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Michael Gelband's PRAX Position: Q2 2026 in Review

Michael Gelband sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 14,742 shares — an estimated $4.75M sold.

Michael Gelband first reported a position in PRAX in Q2 2022 and held it in 5 quarters. The position peaked at $4.75M in Q1 2026. 307 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Michael Gelband reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 14,742 Praxis Precision Medicines shares in Q2 2026, an estimated $4.75M.
Michael Gelband first reported a position in Praxis Precision Medicines in Q2 2022 and held it in 5 quarters.
Michael Gelband's Praxis Precision Medicines position peaked at $4.75M in Q1 2026.
307 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.